



Testing and insights for **every step along the reproductive journey**

Quest Diagnostics[®] is your single source for comprehensive screening and diagnostics—from fertility and planning through pregnancy and wellness.



Fertility and planning



Carrier screening



Testing by trimester



For patients considering pregnancy

Diagnostic insights with enhanced clarity, so you may help your patients get pregnant faster

Rather than traditional testing methods, choose **ReproSource**[®], a Quest Diagnostics company for fertility testing, for actionable insights, easy-to-use tests, and easy-to-interpret reports.

ReproSource gives you the insights you need to help address infertility earlier

With **ReproSource**, a Quest Diagnostics company for fertility testing, you can proactively offer advanced, affordable fertility testing to every couple at risk of infertility that may help them get pregnant faster.

The Ovarian Assessment Report™ (OAR)

Using multiple reproductive hormones, patient age, and advanced mathematics, the OAR can better identify women at risk for low ovarian reserve.

At-home collection for semen analysis test

With at-home collection, male patients provide specimens in the comfort of their homes, avoiding potential issues of inconvenience, distance, or lack of privacy.



ReproSource[®]

A Quest Diagnostics Company

Beyond fertility testing: Our exceptional services make every day easier



Specimen collection kits to simplify collection and transport



Insurance submissions and appeals



Patient-friendly reports



A vast network of experts in fertility, hematology, immunology, endocrinology, and genetics are available for consultation

For more information about fertility testing with **ReproSource**, please visit or call us:

 [FertilityTestingforHCP.com](https://www.ReproSource.com)

 1.800.667.8893



Maximize clinical insights while minimizing uncertainty

An important option for patients considering pregnancy

Genetic carrier screening provides a better understanding of the likelihood and potential impact of inherited genetic disorders. The American College of Obstetricians and Gynecologists (ACOG) recommends that all individuals, regardless of race or ethnicity, be offered screening for the same set of conditions.¹

Before pregnancy

This resource provides a sampling of our comprehensive test menu. The determination of what testing is medically appropriate, including whether each of the individual components are appropriate, must be made by the ordering provider.

Genetic carrier screening

LABORATORY SCREENING OPTIONS	QUEST TEST	TEST CODE
Pan-ethnic carrier screen	QHerit® Carrier Screening An ideal panel for each patient: for a complete list of genes included in each QHerit panel, visit QHerit.com	
	421 diseases^a, 421 genes Our most comprehensive panel , offering the greatest insights	Female: 12593 Male: 12594 ^a
	150 diseases^a, 150 genes Expands upon our midsize panel with medically guided screening	Female: 39866 Male: 39987 ^a
	84 diseases^a, 85 genes A midsize panel that expands upon the most common diseases	Female: 39867 Male: 39988 ^a
	22 diseases^a, 24 genes The most common diseases , including cystic fibrosis (CF), spinal muscular atrophy (SMA), fragile X, and Tay-Sachs	94372
Prenatal carrier screen	Prenatal Carrier Panel^b Includes CFvantage® (cystic fibrosis), spinal muscular atrophy (SMA), fragile X	93349
Cystic fibrosis	CFvantage® Cystic Fibrosis Expanded Screen 161 CF variants, including the 23 common variants aligned with ACOG guidelines ²	92068
Fragile X	XSense®, Fragile X with Reflex^c	16313
Spinal muscular atrophy	SMA Carrier Screen	39445

^a Panel components for males do not include specified X-linked diseases.

^b Individual testing is available for partners of known carriers.

^c Reflex testing may be performed at an additional charge.

While we offer comprehensive testing, some patients may have an interest in screening for a specific disorder, such as cystic fibrosis. For these patients, Quest Diagnostics offers single-gene screening.

Consultation is available on genetic test selection and results interpretation.

Call 1.866.GENE.INFO (1.866.436.3463) Monday through Friday 8:30 AM to 8:00 PM EST

Our QHerit Carrier Screening portfolio offers 4 clinically relevant and medically appropriate panels, screening for up to 421 diseases to provide greater insights that can help determine carrier risks of inherited genetic disease. See important information* on page 8.



Starts with a noninvasive, simple blood draw



Clinically relevant results



No Surprise patient program



Screening is an important part of a healthy pregnancy

Appropriate prenatal testing is a crucial part of caring for people who are expecting

This resource provides a sampling of our comprehensive test menu. The determination of what testing is medically appropriate, including whether each of the individual components are appropriate, must be made by the ordering provider.

1st trimester

LABORATORY SCREENING OPTIONS	QUEST TEST	TEST CODE
OB panel (tests can be ordered as a panel or individually)^d	Obstetric Panel	20210
OB panel, individual components	Complete blood count (CBC) (includes Differential and Platelets)	6399
	Antibody Screen, red blood cells (RBC) with Reflex to Identification, Titer, and Antigen Typing^e	795
	ABO Group and Rh Type	7788
	Rapid plasma reagin (RPR) (Diagnosis) with Reflex to Titer and Confirmatory Testing^e (non-treponemal screening for syphilis)	36126
	Hepatitis B Surface Antigen with Reflex Confirmation^e	498
	Rubella Antibody (IgG), Immune Status	802
Additional OB Panel	Obstetric Panel with Fourth Generation HIV, Hepatitis C Antibody with Reflex	12075
Additional OB Panel component	Hepatitis C Antibody with Reflex to HCV, RNA, Quantitative, Real-Time PCR	8472
Additional OB Panel	Obstetric Panel with Fourth Generation HIV Individual components^d	93802
Additional OB Panel component	HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes^e	91431
Additional 1st trimester tests		
Cervical cytology screening, if indicated ^e	Image-Guided Pap with Age-Based Screening Protocols^e	91384
	Image-Guided Pap with Age-Based Screening with CT/NG^e	91385
	Image-Guided Pap with Age-Based Screening with CT/NG, <i>Trichomonas</i>^e	91386
	Pap alone	See note ^e
Urinalysis/Urine culture	Urinalysis, Complete	5463
	Urinalysis, Complete, with Reflex to Culture^e	3020
	Culture, Urine, Routine	395
TSH	TSH, Pregnancy	90896
	The American Association of Clinical Endocrinologists recommends TSH measurement in women of childbearing age before pregnancy or during the first trimester.	
Zika testing	Zika Virus RNA, Qualitative, Real-Time RT-PCR	93870
	Zika Virus RNA, Qualitative, Real-Time RT-PCR Panel, Serum/Urine	94221
	Zika Virus RNA, Qualitative Real-Time RT-PCR, Serum/Urine and IgM Panel	36758
	Although rates of Zika virus infection have decreased in the United States, obstetricians/gynecologists and other healthcare providers should continue to assess their patients for potential exposure based on travel or sexual history and test symptomatic patients with possible exposure and pregnant women with ongoing exposure regardless of symptoms in accordance with the CDC recommendations. ³	
Iron	Iron, TIBC, and Ferritin Panel	5616
	All pregnant women should be screened for anemia with a complete blood count in the first trimester and again at 24 0/7–28 6/7 weeks of gestation. ⁴	

^e Reflex testing may be performed at an additional charge.

^d If Antibody Screen is positive, Antibody Identification, Titer, and Antigen Typing will be performed at an additional charge. If RPR screen is reactive, RPR Titer and FTA Confirmatory testing will be performed at an additional charge. When only a single test, Hepatitis B Surface Antigen, is ordered to diagnose Hepatitis B in a pregnant woman, additional tests such as liver enzymes should be ordered to confirm the diagnosis.

^e The age-based offerings are based on ACOG recommendations and include image-guided Pap tests. Non-imaged Paps as well as conventional Paps are also available at Quest Diagnostics.



LABORATORY SCREENING OPTIONS	QUEST TEST	TEST CODE
Fetal aneuploidy 1st trimester testing		
First Trimester Screen	First Trimester Screen, hCG The screen includes Pregnancy-associated Plasma Protein-A (PAPP-A), human chorionic gonadotropin (hCG), Nuchal Translucency (NT) test; and risk assessments for trisomy 21 and trisomy 18	16145
Noninvasive prenatal screening (NIPS)	QNatal® Advanced	92777
Maternal Serum Screen (Part 1)	Stepwise, Part 1 The screen includes PAPP-A, hCG, NT test; and risk assessments for trisomy 21 and trisomy 18	16463
	Serum Integrated Screen, Part 1 This screen includes PAPP-A; and risk assessments for trisomy 21 and trisomy 18 reported after Part 2	16165
	Sequential Integrated Screen, Part 1 This screen includes PAPP-A, hCG, NT test; and risk assessments for trisomy 21 and trisomy 18	16131
	Integrated Screen, Part 1 This screen includes PAPP-A, NT test; and risk assessments for trisomy 21 and trisomy 18 reported after Part 2	16148
	Chromosomal Microarray, Prenatal, ClariSure® Oligo-SNP Additional diagnostic testing, including fetal molecular tests, is available. Please refer to the Quest Diagnostics Test Directory or call 1.866.GENEINFO (1.866.436.3463) for further information.	90927
Diagnostic fetal testing via chorionic villus sampling (CVS), if indicated	Chromosome Analysis, Chorionic Villus Sample (CVS)	14592
	Chorionic Villus with Reflex to ClariSure® Oligo-SNP	92808
	FISH, Prenatal Screen	14604
	Chromosomal Microarray, Prenatal, ClariSure® Oligo-SNP	90927
Infectious disease 1st trimester tests		
Tuberculosis (TB), if indicated ^f	QuantiFERON®-TB Gold Plus, 1 Tube	36970
	QuantiFERON®-TB Gold Plus, 4 Tubes, Draw Site Incubated	36971
	T-SPOT®.TB	37737
Chlamydia ^g	Chlamydia trachomatis RNA, TMA, Urogenital	11361
Gonorrhea, if indicated ^g	Neisseria gonorrhoeae RNA, TMA, Urogenital	11362
Chlamydia and gonorrhea (for all females ages 15-24 and those who are high risk)	Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA, Urogenital	11363
HIV testing	HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes^c	91431
Hepatitis C testing	Hepatitis C Antibody with Reflex to HCV, RNA, Quantitative, Real-Time PCR^c	8472
	Hepatitis C Antibody with Reflex to HCV RNA, PCR w/Reflex to Genotype, LiPA^c	94345
Syphilis	Syphilis Antibody Cascading Reflex	90349

^c Reflex testing may be performed at an additional charge.

^f Risk factors include known HIV infection; close contact with individuals known or suspected to have TB; medical risk factors such as diabetes, lupus, cancer, alcoholism, and drug addiction; birth in or emigration from countries with high prevalence; being medically underserved; homelessness, and living or working in long-term care facilities, such as correctional institutions, mental health institutions, and nursing homes.

^g If positive, test-of-cure should be performed within 3-4 weeks post-treatment.

QNatal® Advanced prenatal screening

QNatal Advanced is a noninvasive cfDNA prenatal screen that can help identify the most common fetal aneuploidies. In addition, QNatal Advanced can screen for sex chromosome abnormalities and certain microdeletions. See important information** on page 8.

Our interactive cost estimator provides an estimated out-of-pocket responsibility in real time, to give patients an idea of what they might owe.

Patients have access to their estimation at MyNIPTCost.com

CDC recommends STI screening during pregnancy

According to the Centers for Disease Control and Prevention (CDC), pregnant patients should be tested for some STIs starting early in their pregnancy and repeating close to delivery, as needed. They also recommend open, honest conversations with pregnant patients and, when possible, their sex partners about symptoms and any high-risk sexual behaviors.⁵

Making every day easier for your OBGYN office

Specially trained and dedicated Women's Health service specialists are available for your support and service requests, alleviating some of the administrative burdens that can disrupt your day.

Visit QuestDiagnostics.com/OBGYN or call 1.844.QUESTOB (1.844.783.7862)



Maintaining prenatal care is essential, even as the due date approaches

Second and third trimester screening can provide further insights to help ensure a healthy pregnancy and outcome

This resource provides a sampling of our comprehensive test menu. The determination of what testing is medically appropriate, including whether each of the individual components are appropriate, must be made by the ordering provider.

2nd trimester

LABORATORY SCREENING OPTIONS	QUEST TEST	TEST CODE
CBC	CBC (includes Differential and Platelets) This screen includes white blood count (WBC), RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (absolute and percent neutrophils, lymphocytes, monocytes, eosinophils, and basophils)	6399
	CBC (H/H, RBC, Indices, WBC, Plt) This screen includes WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count	1759
Gestational diabetes screening	Glucose, Gestational Screen (50g), 135 Cutoff (ACOG supported 1st step of 2-step gestational diabetes mellitus (GDM) evaluation)	8477
	Glucose, Gestational Screen (50g), 140 Cutoff (ACOG supported 1st step of 2-step GDM evaluation)	19833
	Glucose Tolerance Test, Gestational, 4 Specimens (100g) (ACOG supported 2nd step of 2-step GDM valuation)	6745
Additional 2nd trimester testing		
Quad Screen	Quad Screen This screen includes alpha-fetoprotein (AFP), unconjugated estriol (uE3), hCG, and dimeric inhibin A (DIA); and risk assessments for trisomy 21, trisomy 18, and open neural tube defects (ONTD)	30294
Maternal Serum Screen (Part 2)	Serum Integrated Screen, Part 2 This screen includes AFP, uE3, hCG, DIA, and PAPP-A from Serum Integrated Screen, Part 1; and risk assessments for trisomy 21, trisomy 18, and ONTD	16167
	Stepwise, Part 2 This screen includes AFP, uE3, hCG, DIA, PAPP-A and hCG from Stepwise, Part 1; and risk assessments for trisomy 21, trisomy 18, and ONTD	16465
	Sequential Integrated Screen, Part 2 This screen includes AFP, uE3, hCG, DIA, PAPP-A and hCG from Sequential Integrated Screen, Part 1; and risk assessments for trisomy 21, trisomy 18, and ONTD	16133
	Integrated Screen, Part 2 This screen includes AFP, uE3, hCG, DIA, and PAPP-A, from Integrated Screen, Part 1; and risk assessments for trisomy 21, trisomy 18, and ONTD	16150
Maternal Serum Alpha-Fetoprotein (MSAFP)	Maternal Serum AFP This screen includes AFP and risk assessment for ONTD	5059
Diagnostic fetal testing via amniocentesis, if indicated	Chromosome Analysis, Amniotic Fluid	14590
	Chromosome Analysis, Amniotic Fluid with Reflex to ClariSure® Oligo-SNP, Prenatal	92704
	Alpha-Fetoprotein, Amniotic Fluid and Reflex to AchE and Fetal Hgb	232
	Chromosomal Microarray, Prenatal, ClariSure® Oligo-SNP	90927
	FISH, Prenatal Screen Additional diagnostic testing, including fetal molecular tests, is available. Please refer to the Quest Diagnostics Test Directory or call 1.866.GENE.INFO (1.866.436.3463) for further information.	14604




This resource provides a sampling of our comprehensive test menu. The determination of what testing is medically appropriate, including whether each of the individual components are appropriate, must be made by the ordering provider.

3rd trimester

LABORATORY SCREENING OPTIONS	QUEST TEST	TEST CODE
CBC	CBC (includes Differential and Platelets) This screen includes WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (absolute and percent neutrophils, lymphocytes, monocytes, eosinophils, and basophils)	6399
	CBC (H/H, RBC, Indices, WBC, Plt) This screen includes WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count	1759
D (Rh) antibody screen	Antibody Screen, RBC with Reflex to Identification, Titer, and Antigen Typing^c	795
Group B streptococcal disease	<i>Streptococcus</i> Group B Culture	5617
	<i>Streptococcus</i> Group B with Susceptibility Culture	15090
	<i>Streptococcus</i> Group B DNA, PCR with Broth Enrichment	91768
	<i>Streptococcus</i> Group B DNA, PCR with Broth Enrichment and Reflex to Susceptibility^c	91770
Chlamydia (if patient tested positive or is high-risk due to age or lifestyle)	<i>Chlamydia trachomatis</i> RNA, TMA, Urogenital	11361
Gonorrhea (if patient tested positive or is high-risk due to age or lifestyle)	<i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital	11362
Chlamydia and gonorrhea (if patient tested positive or is high-risk due to age or lifestyle)	<i>Chlamydia trachomatis/Neisseria gonorrhoeae</i> RNA, TMA, Urogenital	11363
RPR (if patient tested positive or is high-risk due to age or lifestyle)	RPR (Diagnosis) with Reflex to Titer and Confirmatory Testing^c	36126
HIV testing (if patient is high-risk due to lifestyle)	HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes^c	91431

Retesting for STIs is important

Pregnant women with gonorrhea or chlamydial infections should be retested within 3 months after treatment.⁶



^c Reflex testing may be performed at an additional charge.

Advanced testing and insights that are more accessible and affordable

We've made testing easy with expansive health plan coverage, flexible financial options, easy-to-use online tools, and specialized support.



Accessible testing

- **In-network for >90% of covered lives^h** and preferred lab network status with major health plans
- **Financial assistance program** helps qualified patients receive testing at no cost or at a reduced patient price
- **MyQuest[®]** helps patients schedule appointments and securely access results



Simplified processes

- **Quantum[®] solutions** make it easy to order tests and get results
- Interfaces with **hundreds of EHR systems**



Specialized support

- **Specialty Testing Services** team provides prior authorization and patient billing support for genetic testing. Visit QuestDiagnostics.com/STS
- **For OBGYNs**, exclusive access to dedicated Women's Health service specialists. Visit QuestDiagnostics.com/OBGYN or call **1.844.QUESTOB (1.844.783.7862)**

^hThis is directional data. It is based on 2020 HealthLeaders membership data of private third-party payers at the Managed Care Organization (MCO) level, as well as Quest internal data. Information is believed to be accurate as of January 1, 2020; however, it is subject to change.



For more information, visit QuestWomensHealth.com



Important information

* QHerit, QHerit Plus, QHerit Extended, QHerit 421, and QHerit 381 are carrier "screening" tests, and they screen for variations in genes linked to certain health disorders, which can be passed from parents to children. QHerit screens 24 genes; QHerit Plus screens 85 genes, QHerit Extended screens 150 genes, QHerit 421 screens 421 genes, and QHerit 381 screens 381 genes. For a full list of genes that each panel in the QHerit family screens, visit QuestDiagnostics.com. If the results from any panel in the QHerit family suggest that a patient may be a carrier of a gene variation that can cause a health disorder in her offspring, it is recommended that her reproductive partner be offered genetic screening, and that genetic counseling be provided. Pregnancy management decisions should not be based on the results of these screening tests alone. As with any test, there may be false positives or false negatives. The positive predictive value of the screening test varies by genetic variation, and may be lower for rare conditions. Each panel in the QHerit family is a laboratory-developed test that has been developed and validated pursuant to the Clinical Laboratory Improvements Amendments of 1988 (CLIA) and, as such, it has not been reviewed by FDA.

** QNatal[®] Advanced is a cell-free DNA (cfDNA) test that screens for increased risk of certain fetal chromosomal abnormalities that may cause birth defects, including trisomy 21 (Down syndrome), trisomy 18, trisomy 13, and certain sex chromosome abnormalities (ie, 45,X, 47,XXY, 47,XXX, and 47,YYY). In addition, if selected as an option, QNatal Advanced can screen for certain microdeletions (ie, 22q, 5p, 1p36, 15q, 11q, 8q, and 4p) that may cause birth defects, and/or for fetal sex. This test does not assess the risk of fetal anomalies such as neural tube defects or ventral wall defects. QNatal Advanced is not recommended before 10 weeks gestation due to a significantly increased risk of a failed result.

QNatal is a "screening" test, not a diagnostic test, and therefore all positive/increased risk results should be followed by genetic counseling and further diagnostic testing and procedures, when clinically indicated. Pregnancy management decisions should not be based on the results of a cfDNA test alone. As with any test, there may be false positives or false negatives. The positive predictive value of the screening test varies by genetic marker, and may be lower for rare conditions. Performance data for the QNatal Advanced may be obtained by contacting Quest Diagnostics at 1.866.GENE.INFO (1.866.436.3463).

QNatal Advanced is a laboratory-developed test that has been developed and validated pursuant to the Clinical Laboratory Improvements Amendments of 1988 (CLIA), and as such it has not been reviewed by FDA.

References

1. ACOG. Committee opinion no. 690: carrier screening in the age of genomic medicine. *Obstet Gynecol.* 2017;129(3):595-596. doi:10.1097/AOG.0000000000001947
2. American College of Obstetricians and Gynecologists Committee on Genetics. Carrier screening for genetic conditions: Committee opinion number 691. March 2017 (Reaffirmed 2020). Accessed January 24, 2023. <https://www.acog.org/-/media/project/acog/acogorg/clinical/files/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions.pdf>
3. ACOG. Committee opinion no. 784: management of patients in the context of Zika virus. *Obstet Gynecol.* 2019;134(3):655-657. doi:10.1097/AOG.0000000000003400
4. ACOG Committee on Practice Bulletins, Anemia in pregnancy: ACOG practice bulletin number 233. *Obstet Gynecol.* 2021;138(2):e55-e64. doi:10.1097/AOG.0000000000004477
5. CDC. STDs during pregnancy - CDC. Updated April 11, 2023. Accessed May 15, 2023. <https://www.cdc.gov/std/pregnancy/stdfact-pregnancy-detailed.htm>
6. CDC. Sexually transmitted infections treatment guidelines, 2021 - pregnant women. Updated July 22, 2021. Accessed May 15, 2023. <https://www.cdc.gov/std/treatment-guidelines/pregnant.htm>

Test codes may vary by location. Please contact your local laboratory for more information.

All laboratory tests are subject to various confounders that can affect the specificity and sensitivity of the test (the test's accuracy). The accuracy of any test is validated under strict criteria intended to help control variables but can never be 100% accurate in all cases.

Image content features models and is intended for illustrative purposes only.

QuestDiagnostics.com

Quest[®], Quest Diagnostics[®], any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—[®] and [™]—are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. SB1925 07/2023